TSHA Q2 2025 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena

TSHATaysha Gene Therapies, Inc.

$1B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+78.6% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$27M-1347.1% margin

Net Income

-$27M-1353.6% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

-13.7%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$333M

Total Liabilities

$85M

Stockholders' Equity

$249M

Cash & Equivalents

$313M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$1M	+78.6%
Gross Profit	$2M	$1M	+78.6%
Operating Income	-$27M	-$21M	-25.6%
Net Income	-$27M	-$21M	-28.4%